We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Aptorum Group has joined forces with Covar Pharmaceuticals for studying the use of three repurposed drug candidates for the treatment of novel coronavirus (COVID-19).
Aptorum Group is set to choose at least three repurposed drug candidates for Covid-19 treatment, out of nearly 2,600 approved small drug molecules screened using its Smart-ACT drug discovery platform.